A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy/Safety of Maridebart Cafraglutide on Mortality, Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction Obesity